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A B S T R A C T
p53 is one of the most frequently mutated genes in human tumors including head and neck tumors like oral squa-
mous cell carcinoma. It might be responsible for more than 50% of all relapses in patients with surgically treated oral
carcinoma and clean margins. The aim of the present study was to explore p53 protein expression in peritumoral tissue
and correlate it with relapse of the disease. The study included 25 patients (17 males and 8 females) with oral squamous
cell carcinoma in the period August 2006 till August 2008. For immunohistochemical assay, a monoclonal antibody
against p53 protein was applied (clone DO-7, DAKO Glostrup, Denmark). Peritumoral expression of p53 was as follows:
10 out of 25 cases (40%) were negative, 2 cases (8%) showed weak, 5 cases (20%) moderate and 8 cases (32%) strong p53
positivity. No significant correlation between peritumoral expression of p53 protein and patient’s relapse was found. In
contrast, we found a trend toward association between intratumoral p53 expression and patient’s relapse (p=0.07). There
was also trend toward higher peritumoral p53 expression in females comparing with p53 expression in males (52.9% of
males did not have p53 expression while 87.5% females had mild, moderate or high p53 expression, p=0.088). Peritu-
moral expression of p53 protein is frequently seen in oral squamous cell carcinoma and merits further research.
Key words: oral carcinoma, squamous cell carcinoma, p53 protein, survival, relapse
Introduction
Oral squamous cell carcinoma (OSCC) is the sixth
most common cancer for both sexes in the general popu-
lation and the third most common cancer in developing
countries with more than 350,000 new cases worldwide
every year1.P53 gene is the most frequently mutated
gene in human tumors2. Disruption of the p53 signaling
pathway is also one of the most common genetic alter-
ations of the head and neck tumors 1,3. Its product, p53
protein, plays a fundamental role in the control of cell
proliferation, apoptosis and genetic stability1, 4. The pro-
gnostic role of p53 protein in OSCC has already been es-
tablished with several studies that pointed out p53 as a
prognosticator of poor outcome though there are studies
that could not confirm its prognostic value3,5,6. Several
studies pointed out that there was no significant differ-
ence in p53 protein expression in relation to different
oral cavity anatomical sites of OSCC7. It is noteworthy
that p53 is also important predictor of radiotherapy re-
sponse in patients with OSCC8,9 Peritumoral expression
of p53 in oral carcinoma is poorly understood with very
few studies that specifically focused on the p53 expres-
sion in peritumoral normal mucosa and its correlation
with outcome10, 11. Early local recurrence is one of the
main causes of treatment failure of OSCC contributing
significantly to low survival rates in these patients12.
Also, clear surgical margins can not predict local recur-
rence in a significant proportion of patients with OSCC.
Therefore we wanted to explore peritumoral expression
of p53 and its correlation with relapse as well as other
clinicopathologic parameters in OSCC.
Materials and Methods
Clinical data
This prospective study included 25 patients (17 males
and 8 females), diagnosed with squamous cell carcinoma
of oral cavity in the period August 2006 till August 2008.
All clinicopathologic data are summarized in Table 1.
The control examinations were performed each 6, 12, 18
and 24 months. The last follow-up data were obtained in
December 2008.
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Histopathology and Immunohistochemistry
Formalin-fixed, paraffin-embedded tissues of 25 pri-
mary oral squamous cell carcinomas were used for rou-
tine diagnosis. The tumor grading was done according
the current WHO classification of the tumors of head and
neck (2005). The tumor staging was done using the 7th
American Joint Committee on Cancer Recommendations
(2010). Immunohistochemical assay for p53 protein was
done using a monoclonal antibody (clone DO-7, DAKO,
Glostrup, Denmark). p53 protein positivity was esti-
mated as follows: < 10% positive cells (negative), 11–40%
positive cells (weak), 41–70% (moderate) and > 71% pos-
itive cells (strong positivity).
Statistical analysis
For correlation analysis Fischer exact test was used.
One-way ANOVA and post-hoc tests were applied to com-
pare means. A computer program package for social sci-
ences (SPSS 11.5, Chicago, IL, USA) was used for all sta-
tistical testing. The statistical significance was accepted
for p<0.05.
Results
Clinico-pathologic characteristics of the cohort are
summarized in Table 1. All tumors were oral squamous
cell carcinomas (lip and oral cavity) (Figure 1) of which 9
(36%) were low grade whereas 15 (60%) were intermedi-
ate and 1 (4%) high grade. Significantly high tumor
grades were found among females than among males
(p=0.032, Fischer’s exact test, Table 2). Similarly, a
higher percentage of females were in stage pT2 com-
pared with males (p=0.022, Fisher’s exact test). During
the follow-up period 6 patients (24%) had relapse of the
disease (2 females and 4 males). Peritumoral expression
of p53 was as follows: 10 out of 25 cases (40%) were nega-
tive, 2 cases (8%) showed weak, 5 cases (20%) moderate
and 8 cases (32%) strong p53 positivity (Table 3, Figure
2A-D). Intratumoral p53 protein expression had the fol-
lowing distribution: Five (20%) out of 25 tumors showed
negative staining of p53 protein whereas 11 (44%)
showed weak, 4 (16%) moderate and 5 (20%) strong p53
protein overexpression. We did not find a significant cor-
relation between peritumoral expression of p53 protein
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TABLE 1
CLINICAL, HISTOPATHOLOGIC AND IMMUNOHISTOCHEMICAL
FEATURES OF 25 PATIENTS WITH OSCC
Characteristic Number of patients (%)
Age (mean, range) 65.88 (49–92)
Sex Males: 17 (68%)
Females: 8 (32%)
Tumor stage pT1: 6 (24%)
pT2: 17 (68%)
pT3: 2 (8%)
Lymph node status No: 21 (84%)
N1: 2 (8%)
N2: 2 (8%)
Metastasis Mo: 23 (92%)
M1: 2 (8%)









Smoking Smokers: 13 (52%)
Non-smokers: 12 (48%)
Alcohol consumption Yes: 3 (12%)
No: 22 (88%)
Relapse of the disease Yes: 6 (24%)
No: 19 (76%)
Fig. 1. A patient with squamous cell carcinoma before sugery (a)
and after surgery (b).
TABLE 2
SIGNIFICANTLY DIFFERENT DISTRIBUTION OF THE TUMOR
GRADE BETWEEN GENDERS
Sex Grade 1 Grade 2 Grade 3 Total
Male 8 (32%) 8 (32%) 1 (4%) 17 (68%)
Female 0 8 (32%) 0 8 (32%)
Total 8 (32%) 16 (64%) 1 (4%) 25 (100%)
TABLE 3
DISTRIBUTION OF PERITUMORAL P53 PROTEIN EXPRESSION












Male 10 (40%) 1 (4%) 2 (8%) 4 (16%) 17 (68%)
Female 0 1 (4%) 3 (12%) 4 (16%) 8 (32%)
Total 10 (40%) 2 (8%) 5 (20%) 8 (32%) 25 (100%)
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and patients’ relapse. In contrast, we found a trend of
correlation between intratumoral p53 expression and pa-
tient’s relapse (p=0.07). There was also trend toward
higher peritumoral p53 expression in females comparing
with p53 expression in males (52.9% of males did not
have p53 expression while 87.5% female tissue samples
showed p53 expression, p=0.088). We found also signifi-
cant correlation between p53 expression and patient’s
age (p=0.031). No other significant correlation between
the variables was found.
Discussion
Peritumoral p53 protein expression was detected in
52% of OSCC analyzed in our study. This is in accordance
with other studies that also demonstrated high p53 pro-
tein positivity in surgical margins although these were
previously morphologically stated to be clean11. Several
studies have already pointed out that clear surgical mar-
gins could not predict the relapse of the disease in a sig-
nificant percentage of OSCC cases. This discrepancy may
be caused by p53 alterations in the peritumoral tissue as
our results also indicate (see Table 4). However, we could
not find a significant association between peritumoral
p53 expression and local recurrence. This can be par-
tially explained by a small sample size and a relatively
short follow-up of the patients included in our study al-
though the most local recurrences occur within two first
years after the initial diagnosis. Unlike other studies,
intratumoral expression of p53 protein was not high as
expected since only 36% of the cases showed moderate
and strong nuclear p53 expression. The most studies
found p53 protein overexpression in OSCC in approxi-
mately 50% of the cases7,13–16. The elucidation of such
finding might be that we had a relatively small percent-
age of high grade tumors and the most tumors were in its
early stage (pT1 and pT2). Also, such a discrepancy can
be explained by other factors including the methodology
employed, type of tumor material and heterogeneity of
tumoral sites examined in our study. We also could not
confirm statistically significant association between tu-
mor expression of p53 protein and relapse of the disease
although there was a trend toward a significant associa-
tion (p=0.07). It is noteworthy that the prognostic value
of the tumor p53 expression is somewhat contradictory
although more studies confirmed p53 as a prognosticator
of poor outcome5, 17.
Peritumoral p53 protein expression showed signifi-
cant positive relationship with the tumor size since the
larger tumors showed higher p53 expression. It is not
surprising since the loss of p53 gene function is related to
increased cell proliferation and tumor neoangiogenesis18.
However, it is not well understood how peritumoral cells
influenced the tumor growth although the relationship
between the tumor stroma and tumor cells has been es-
tablished and well documented19.We also want to point
out that high percentage of the patients included in the
study were smokers (Table 1). Smoking is a well estab-
lished risk factor not only for oral carcinoma but also for
several other malignant and non-malignant conditions20
though clear relationship between smoking and p53 mu-
tation has not been established yet21. This public health
problem needs to be resolved as soon as possible since it
dramatically might reduce the incidence of OSCC as the
third most common cancer in developing countries1. This
is particularly important if we know that overall five-
-year survival in patients with OSCC was among the low-
est with an average of 54% in the United States21. There
is no relevant data about survival rate of the patients in
Bosnia and Herzegovina but it probably is lower than in
the United States.
Conclusion
In summary, there was no significant correlation be-
tween peritumoral expression of p53 and relapse whereas
we found a trend toward correlation between intratumo-
ral p53 expression and relapse of the disease. Peritumo-
ral p53 expression was significantly associated with the
tumor size. Although small sample size in our study did
not allow revealing statistically significant association
between p53 expression within tumor cells and cancer
relapse, further research involving larger sample size is
warranted.
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Fig. 2. Illustrating various expressions of p53 protein in peritu-
moral tissue.
TABLE 4
A SUMMARY OF THE KEY CORRELATION FINDINGS
Variables n (%) n (%) p-value
Tumor size Size 1 Size 2–3
Positive p53 expression on
mucosal margins
2 (33.0) 0 0.05
Tumor grade Grade 1 Grades 2–3
Positive p53 expression on
mucosal margins
2 (25.0) 0 0.093
Tumor relapse No relapse Relapse
Positive p53 expression in
tumor cells
17 (89.5) 3 (50) 0.07
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PERITUMORSKA EKSPRESIJA P53 KOD KARCINOMA USNE [UPLJINE
S A @ E T A K
P53 je jedan od naj~e{}e mutiranih gena kod tumora, uklju~uju}i tumore kao {to je planocelularni karcinom glave i
vrata. Mogao bi biti odgovoran za vi{e od 50% relapsa kod bolesnika kod kojih je tumor odstranjen kirur{ki, uz nega-
tivne rubove. Cilj ovog istra`ivanja je odrediti ekspresiju p53 u peritumorskom tkivu i usporediti sa relapsima bolesti.
Studija je uklju~ivala 25 bolesnika (17 mu{kih i 8 `enskih) sa planocelkularnim karcinomom u razdoblju od kolovoza
2006 do kolovoza 2008. Monoklonalno protutijelo protiv p53 je upotrebljavano za imunohistokemijsku analizu (clone
DO-7), DAKO Glostrup, Denmark). Peritumorska espresija p53 je bila slijede}a: 10 od 25 slu~ajeva su bili negativni
(40%), 2 su pokazala slabu ekspresiju (8%), 5 umjerenu (20%), a 8 jaku ekspresiju p53 (32%). Nije na|ena zna~ajna
korelacija izme|u peritumorske p53 ekspresije i relapsa. Nasuprot tome, na{li smo povezanodst izme|u intratumoralne
p53 ekspresije i relapsa (p=0.07). Tako|er je postojala vi|a peritumoralna ekspresija p53 kod `ena prema mu{karcima.
Peritumoralna ekspresija p53 se ~esto vidi kod karcinoma usne {upljine i zaslu`uje daljnja istra`ivanja.
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